Owkin
Gregory Taylor, MBA, currently serves as Vice President of Global Commercial Diagnostics at Owkin since July 2023. Previously, Gregory held several key positions at Roche from June 2015 to March 2023, including Head of International Business Leader & Market Development and Director of Enterprise Sales for North America, focusing on oncology, next-generation sequencing, and software solutions. Prior roles include Regional Account Manager at RainDance Technologies, Senior Molecular Account Executive at GenMark Diagnostics, and Director of Business Development at HTG Molecular Diagnostics. Gregory began a career in research as an R&D Scientist at Biotransplant Inc. and as a Research Associate at Boston Medical Center. Academically, Gregory holds an MBA from Isenberg School of Management, UMass Amherst, and a Bachelor of Science in Microbiology from the University of Massachusetts Amherst.
This person is not in any teams
This person is not in any offices
Owkin
6 followers
Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.